The study is to evaluate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy for patients with maligant glioblastoma multiforme. Autologous TiLs should be given by intravenous infusion after 5 days of lymphodepletion treatment.

Inclusion Criteria:

1. Age: 18 to 80 years old;

2. Has at least one measurable tumor foci;

3. ECOG score range : 0-2;

4. Expected survival time: ≥ 3 months;

5. All screening labs should be performed 7 days prior to registration.The laboratory results need to meet below criteria:

   • Absolute white blood cell counts (WBC) ≥ 3.0×10^9/L；
   • Platelet count (PLT) ≥ 100×10^9/L；
   • Hematological Absolute neutrophil count (ANC) ≥ 1.5×10^9/L；
   • Hemoglobin (HGB) ≥ 90g/L;
   • Albumin (absolute) ≥ 2.8g/dL;
   • Serum ALT/AST ≤ 2.5×ULN (for patients with liver metastasis ≤ 5×ULN);
   • Total bilirubin (TBIL) ≤ 1.5×ULN (for patients with liver metastasis ≤ 2×ULN);
   • Renal Serum creatinine OR measured or calculated a creatinine clearance (CR) ≤1.5×ULN OR≥ 50 mL/min for participant;
   • AST/ALT (SGOT) ≤ 2.5×ULN (for patients with liver metastasis ≤ 5×ULN);
   • International Normalized Ratio (INR) ≤ 1.5;
   • Prothrombin Time (PT) and Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN;

6. Female participant of childbearing potential should have a negative result of human chorionic gonadotropin (HCG) test. The participants must take contraception during the entire clinical follow-up.

7. Be willing and able to provide written informed consent/assent for the trial.

Exclusion Criteria:

1. Has systemic active infection and requiring treatment;

2. Has severe physical or mental illness;

3. Has active rheumatic disease;

4. Has any kinds of organ transplantation;

5. Being pregnant or lactating;

6. Enrolled in other clinical trials within 4 weeks prior to registration;

7. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C;

8. Other conditions that the researcher considered to be excluded;

9. Has taken blow treatment before enrollment:

   • Received systemic immunosuppressive treatments, aside from corticosteroids within 14 days of treatment;
   • Plan to get inactivated vaccine 28 days prior/during, or 60 days post the treatment.